KR20230031320A - 2-[4-[(2,3,4-트리메톡시페닐)메틸]피페라진-1-일]에틸 피리딘-3-카르복실레이트의 결정 형태 및 합성 방법 - Google Patents

2-[4-[(2,3,4-트리메톡시페닐)메틸]피페라진-1-일]에틸 피리딘-3-카르복실레이트의 결정 형태 및 합성 방법 Download PDF

Info

Publication number
KR20230031320A
KR20230031320A KR1020237003155A KR20237003155A KR20230031320A KR 20230031320 A KR20230031320 A KR 20230031320A KR 1020237003155 A KR1020237003155 A KR 1020237003155A KR 20237003155 A KR20237003155 A KR 20237003155A KR 20230031320 A KR20230031320 A KR 20230031320A
Authority
KR
South Korea
Prior art keywords
compound
formula
free base
composition
reacting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237003155A
Other languages
English (en)
Korean (ko)
Inventor
닐 버클리
댄 벨몬트
사라 베툰
크리스타 디아즈
브라이언 하우저
명 구 김
쿠마르 칸난
Original Assignee
임브리아 파마슈티칼스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 임브리아 파마슈티칼스, 인크. filed Critical 임브리아 파마슈티칼스, 인크.
Publication of KR20230031320A publication Critical patent/KR20230031320A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
KR1020237003155A 2020-06-30 2021-06-28 2-[4-[(2,3,4-트리메톡시페닐)메틸]피페라진-1-일]에틸 피리딘-3-카르복실레이트의 결정 형태 및 합성 방법 Pending KR20230031320A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063046123P 2020-06-30 2020-06-30
US202063046120P 2020-06-30 2020-06-30
US63/046,120 2020-06-30
US63/046,123 2020-06-30
PCT/US2021/039305 WO2022005928A1 (en) 2020-06-30 2021-06-28 Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin -1-yl]ethyl pyridine-3-carboxylate and methods of synthesis

Publications (1)

Publication Number Publication Date
KR20230031320A true KR20230031320A (ko) 2023-03-07

Family

ID=79314883

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237003155A Pending KR20230031320A (ko) 2020-06-30 2021-06-28 2-[4-[(2,3,4-트리메톡시페닐)메틸]피페라진-1-일]에틸 피리딘-3-카르복실레이트의 결정 형태 및 합성 방법

Country Status (8)

Country Link
EP (1) EP4171233A4 (https=)
JP (2) JP7792920B2 (https=)
KR (1) KR20230031320A (https=)
CN (1) CN116056711B (https=)
AU (1) AU2021299266A1 (https=)
CA (1) CA3188286A1 (https=)
IL (1) IL299547A (https=)
WO (1) WO2022005928A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023235297A1 (en) * 2022-06-03 2023-12-07 Imbria Pharmaceuticals, Inc. Compounds and methods for increasing efficiency of cardiac metabolism

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9169279B2 (en) * 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
CN102850296B (zh) * 2012-09-29 2015-01-07 瑞阳制药有限公司 曲美他嗪的制备方法
IL283725B2 (en) * 2017-06-20 2024-04-01 Imbria Pharmaceuticals Inc Compositions and methods for increasing efficiency of cardiac metabolism
EP3976103A4 (en) * 2019-05-31 2023-06-28 Imbria Pharmaceuticals, Inc. Methods of altering cardiac remodeling using compounds that promote glucose oxidation
EP3976101A4 (en) * 2019-05-31 2023-06-21 Imbria Pharmaceuticals, Inc. FIBROSIS TREATMENT METHODS USING COMPOUNDS THAT PROMOTE GLUCOSE OXIDATION

Also Published As

Publication number Publication date
JP2026027462A (ja) 2026-02-18
JP2023532330A (ja) 2023-07-27
WO2022005928A1 (en) 2022-01-06
AU2021299266A1 (en) 2023-02-02
JP7792920B2 (ja) 2025-12-26
IL299547A (en) 2023-02-01
CN116056711B (zh) 2026-03-31
EP4171233A1 (en) 2023-05-03
CN116056711A (zh) 2023-05-02
CA3188286A1 (en) 2022-01-06
EP4171233A4 (en) 2024-08-21

Similar Documents

Publication Publication Date Title
JP7174132B2 (ja) オメカムチブメカルビルの塩及び塩を調製するプロセス
TWI804933B (zh) 用作cdk7激酶抑制劑的化合物及其應用
JP2022517396A (ja) Ｅｇｆｒ阻害剤の塩、結晶形及びその製造方法
US20250074878A1 (en) Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
JP2026027462A (ja) ピリジン－３－カルボン酸２－［４－［（２，３，４－トリメトキシフェニル）メチル］ピペラジン－１－イル］エチルの結晶形態および合成方法
CN110218184A (zh) 诺德司他共晶及其制备方法
ES2814499T3 (es) Formas en estado sólido de sales de Nilotinib
CN111320583A (zh) 诺德司他新晶型及其制备方法
CN115536654A (zh) 小檗碱橙皮素盐晶型及其制备方法和其组合物与应用
WO2018085932A1 (en) Novel crystalline forms of lesinurad
CN117105854B (zh) 一种米力农-烟酸晶体以及制备方法
TWI907075B (zh) 一種嘧啶苯胺類化合物的晶型、製備方法及應用
CN105228988A (zh) 曲格列汀半琥珀酸盐的晶体及其制备方法和药物组合物
JP2019506455A (ja) Ｎ−（４，５−ビスメタンスルホニル−２−メチルベンゾイル）グアニジン塩酸塩およびｎ−（４，５−ビスメタンスルホニル−２−メチルベンゾイル）グアニジン塩の結晶変態
CN109422723B (zh) 一种肠2b型磷酸钠协同转运蛋白抑制剂的晶型及其制备方法
WO2026040323A1 (zh) 一种依鲁替尼单月桂醇硫酸盐、制备方法、应用
WO2026021534A1 (zh) 一种嘧啶类衍生物的固体形式及其制备方法和应用
CN116813541A (zh) 米力农药用共晶体及其制备方法
WO2015109925A1 (zh) 丙型肝炎药物的晶型及其制备方法、其药物组合物和用途
HK1218544B (en) Salt of omecamtiv mecarbil and process for preparing salt
HK1219484B (zh) 心肌肌球蛋白激动剂的盐和制备盐的方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000